396 related articles for article (PubMed ID: 18334512)
1. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
Dawood S; Broglio K; Esteva FJ; Ibrahim NK; Kau SW; Islam R; Aldape KD; Yu TK; Hortobagyi GN; Gonzalez-Angulo AM
Ann Oncol; 2008 Jul; 19(7):1242-1248. PubMed ID: 18334512
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.
Olson EM; Najita JS; Sohl J; Arnaout A; Burstein HJ; Winer EP; Lin NU
Breast; 2013 Aug; 22(4):525-31. PubMed ID: 23352568
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
Dawood S; Broglio K; Buzdar AU; Hortobagyi GN; Giordano SH
J Clin Oncol; 2010 Jan; 28(1):92-8. PubMed ID: 19933921
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
[TBL] [Abstract][Full Text] [Related]
6. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
[TBL] [Abstract][Full Text] [Related]
7. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.
Swain SM; Baselga J; Miles D; Im YH; Quah C; Lee LF; Cortés J
Ann Oncol; 2014 Jun; 25(6):1116-21. PubMed ID: 24685829
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease.
Pieńkowski T; Zielinski CC
Ann Oncol; 2010 May; 21(5):917-24. PubMed ID: 19717536
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Olson EM; Abdel-Rasoul M; Maly J; Wu CS; Lin NU; Shapiro CL
Ann Oncol; 2013 Jun; 24(6):1526-33. PubMed ID: 23463626
[TBL] [Abstract][Full Text] [Related]
11. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
Lai R; Dang CT; Malkin MG; Abrey LE
Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
[TBL] [Abstract][Full Text] [Related]
12. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
15. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
16. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
17. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.
Hurvitz SA; O'Shaughnessy J; Mason G; Yardley DA; Jahanzeb M; Brufsky A; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Chu L; Li H; Antao V; Cobleigh M
Clin Cancer Res; 2019 Apr; 25(8):2433-2441. PubMed ID: 30593513
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab and survival of patients with metastatic breast cancer.
Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
Kim MM; Dawood S; Allen P; Sahin AA; Woodward WA; Smith BD; Strom EA; Hunt KK; Meric-Bernstam F; Gonzalez-Angulo AM; Buchholz TA
Cancer; 2012 Oct; 118(20):4936-43. PubMed ID: 22511276
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]